217 related articles for article (PubMed ID: 36076991)
1. Secretory SERPINE1 Expression Is Increased by Antiplatelet Therapy, Inducing MMP1 Expression and Increasing Colon Cancer Metastasis.
Kim WT; Mun JY; Baek SW; Kim MH; Yang GE; Jeong MS; Choi SY; Han JY; Kim MH; Leem SH
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076991
[TBL] [Abstract][Full Text] [Related]
2. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
3. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Golino P
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet therapy in acute coronary syndromes.
Grove EL; Würtz M; Thomas MR; Kristensen SD
Expert Opin Pharmacother; 2015; 16(14):2133-47. PubMed ID: 26293612
[TBL] [Abstract][Full Text] [Related]
6. A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs.
Fayaz SM; Rajanikant GK
Curr Pharm Des; 2012; 18(12):1625-34. PubMed ID: 22360514
[TBL] [Abstract][Full Text] [Related]
7. Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor.
Sun MT; Huang S; Wiviott SD; Antman EM; Roe MT; Ohman EM; Neely M; Wallentin L; Wong CX
Am J Cardiol; 2020 Apr; 125(8):1280-1283. PubMed ID: 32081368
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.
Jeong YH; Bliden KP; Antonino MJ; Park KS; Tantry US; Gurbel PA
Am Heart J; 2012 Jul; 164(1):35-42. PubMed ID: 22795280
[TBL] [Abstract][Full Text] [Related]
9. Contemporary use of P2Y
Rakowski T; Siudak Z; Dziewierz A; Plens K; Kleczyński P; Dudek D
J Thromb Thrombolysis; 2018 Jan; 45(1):151-157. PubMed ID: 29075924
[TBL] [Abstract][Full Text] [Related]
10. Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
Baos S; Underwood W; Culliford L; Reeves BC; Rogers CA; Bowles R; Johnson T; Baumbach A; Mumford A
Trials; 2017 Nov; 18(1):529. PubMed ID: 29121979
[TBL] [Abstract][Full Text] [Related]
11. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and clinical implications of switching between P2Y12 receptor antagonists: considerations for practice.
Bagai A; Chua D; Cohen EA; Saw J; Verma S; Vijayaraghavan R; Welsh R; Fitchett D
Crit Pathw Cardiol; 2014 Dec; 13(4):156-8. PubMed ID: 25396293
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of clopidogrel.
Sarafoff N; Byrne RA; Sibbing D
Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
[TBL] [Abstract][Full Text] [Related]
14. Platelet function testing as a biomarker for efficacy of antiplatelet drugs.
Lordkipanidzé M; So D; Tanguay JF
Biomark Med; 2016 Aug; 10(8):903-18. PubMed ID: 27414976
[TBL] [Abstract][Full Text] [Related]
15. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
[TBL] [Abstract][Full Text] [Related]
16. P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Liu F; Tantry US; Gurbel PA
Expert Opin Pharmacother; 2015 Jun; 16(8):1149-65. PubMed ID: 25873127
[TBL] [Abstract][Full Text] [Related]
17. Utility of the Aspirin and P2Y12 Response Assays to Determine the Effect of Antiplatelet Agents on Platelet Reactivity in Traumatic Brain Injury.
Parry PV; Choi PA; Bauer JS; Panczykowski DM; Puccio AM; Okonkwo DO
Neurosurgery; 2017 Jan; 80(1):92-96. PubMed ID: 28362884
[TBL] [Abstract][Full Text] [Related]
18. Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Thomas MR; Outteridge SN; Ajjan RA; Phoenix F; Sangha GK; Faulkner RE; Ecob R; Judge HM; Khan H; West LE; Dockrell DH; Sabroe I; Storey RF
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2562-70. PubMed ID: 26515417
[TBL] [Abstract][Full Text] [Related]
19. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Kamran H; Jneid H; Kayani WT; Virani SS; Levine GN; Nambi V; Khalid U
JAMA; 2021 Apr; 325(15):1545-1555. PubMed ID: 33877270
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Guimarães PO; Tricoci P
Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
